Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma

The PI3K/Akt/mTOR pathway is overactivated and heat shock protein (HSP) 90 is overexpressed in common cancers. We hypothesized that targeting both pathways can kill intrahepatic cholangiocarcinoma (CCA) cells. HSP90 and PTEN protein expression was evaluated by immunohistochemical staining of samples from 78 patients with intrahepatic CCA. CCA cell lines and a thioacetamide (TAA)-induced CCA animal model were treated with NVP-AUY922 (an HSP90 inhibitor) and NVP-BEZ235 (a PI3K/mTOR inhibitor) alone or in combination. Both HSP90 overexpression and loss of PTEN were poor prognostic factors in patients with intrahepatic CCA. The combination of the HSP90 inhibitor NVP-AUY922 and the PI3K/mTOR inhibitor NVP-BEZ235 was synergistic in inducing cell death in CCA cells. A combination of NVP-AUY922 and NVP-BEZ235 caused tumor regression in CCA rat animal model. This combination not only inhibited the PI3K/Akt/mTOR pathway but also induced ROS, which may exacerbate the vicious cycle of ER stress. Our data suggest simultaneous targeting of the PI3K/mTOR and HSP pathways for CCA treatment.

[1]  Jianjun Zhang,et al.  The heat shock protein 90 inhibitor 17-AAG suppresses growth and induces apoptosis in human cholangiocarcinoma cells , 2013, Clinical and Experimental Medicine.

[2]  P. Workman,et al.  Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX , 2013, Oncotarget.

[3]  G. Riggins,et al.  Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy , 2013, Tumor Biology.

[4]  Geraint T. Williams,et al.  PTEN loss and KRAS activation cooperate in murine biliary tract malignancies , 2013, The Journal of pathology.

[5]  Xiangliang Zhang,et al.  High Expression of Heat Shock Protein 90 Is Associated with Tumor Aggressiveness and Poor Prognosis in Patients with Advanced Gastric Cancer , 2013, PloS one.

[6]  T. Yap,et al.  Development of therapeutic combinations targeting major cancer signaling pathways. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Chi-Ying F. Huang,et al.  Gene expression‐based chemical genomics identifies heat‐shock protein 90 inhibitors as potential therapeutic drugs in cholangiocarcinoma , 2013, Cancer.

[8]  A. Maitra,et al.  Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer , 2012, Oncotarget.

[9]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[10]  C. Fegan,et al.  The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells , 2012, Oncotarget.

[11]  J. Larkin,et al.  A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma , 2012, Investigational New Drugs.

[12]  Paul Workman,et al.  Hsp90 Molecular Chaperone Inhibitors: Are We There Yet? , 2012, Clinical Cancer Research.

[13]  Kwok-Kin Wong,et al.  Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. , 2011, Cancer cell.

[14]  Ju-Hee Lee,et al.  Antitumor activity of NVP‐AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins , 2011, Cancer science.

[15]  W. Weng,et al.  Characterization of a novel rat cholangiocarcinoma cell culture model-CGCCA. , 2011, World journal of gastroenterology.

[16]  S. Grant.  Enhancing proteotoxic stress as an anticancer strategy , 2011, Oncotarget.

[17]  Andrei V. Gudkov,et al.  Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib , 2011, Oncotarget.

[18]  A. Zhu,et al.  Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities , 2011, Hepatology.

[19]  J. Tabernero,et al.  Targeting the PI3K/Akt/mTOR Pathway – Beyond Rapalogs , 2010, Oncotarget.

[20]  G. Giaccone,et al.  Targeting the dynamic HSP90 complex in cancer , 2010, Nature Reviews Cancer.

[21]  A. Zhu,et al.  Genetics of biliary tract cancers and emerging targeted therapies. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Vassal,et al.  Mechanistic Evaluation of the Novel HSP90 Inhibitor NVP-AUY922 in Adult and Pediatric Glioblastoma , 2010, Molecular Cancer Therapeutics.

[23]  D. Cunningham,et al.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. , 2010, The New England journal of medicine.

[24]  P. Atadja,et al.  Synergistic action of the novel HSP90 inhibitor NVP‐AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma , 2010, European journal of haematology.

[25]  G. Hotamisligil,et al.  Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease , 2010, Cell.

[26]  A. S. Sreedhar,et al.  Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma. , 2009, Biochemical pharmacology.

[27]  J. Wolchok,et al.  Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma , 2008, Clinical Cancer Research.

[28]  Y. Bayraktar,et al.  Cholangiocarcinoma: a compact review of the literature. , 2008, World journal of gastroenterology.

[29]  J. Baselga,et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. , 2008, Cancer research.

[30]  T. Yen,et al.  Animal PET for Thioacetamide-Induced Rat Cholangiocarcinoma: A Novel and Reliable Platform , 2008, Molecular Imaging and Biology.

[31]  W. Jochum,et al.  Rare PIK3CA hotspot mutations in carcinomas of the biliary tract , 2008, Genes, chromosomes & cancer.

[32]  Joseph Schoepfer,et al.  NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models , 2008, Breast Cancer Research.

[33]  R. Kaufman,et al.  Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? , 2007, Antioxidants & redox signaling.

[34]  F. Mollinedo,et al.  Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells. , 2007, Cancer research.

[35]  P. Walter,et al.  Signal integration in the endoplasmic reticulum unfolded protein response , 2007, Nature Reviews Molecular Cell Biology.

[36]  G. Gores,et al.  Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. , 2006, The Journal of clinical investigation.

[37]  M. Drysdale,et al.  Targeting Hsp90 for the treatment of cancer. , 2006, Current opinion in drug discovery & development.

[38]  J. McCubrey,et al.  Kinase-addiction and bi-phasic sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to imatinib and geldanamycin , 2005, Cancer biology & therapy.

[39]  H. El‐Serag,et al.  The epidemiology of cholangiocarcinoma. , 2004, Seminars in liver disease.

[40]  Y. Jan,et al.  Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: an animal model recapitulating the multi-stage progression of human cholangiocarcinoma. , 2003, Carcinogenesis.

[41]  M. Blagosklonny.  Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs , 2002, Leukemia.

[42]  P. Sancho,et al.  Effect of Glutathione Depletion on Antitumor Drug Toxicity (Apoptosis and Necrosis) in U-937 Human Promonocytic Cells , 2001, The Journal of Biological Chemistry.

[43]  T. Patel.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States , 2001, Hepatology.

[44]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[45]  I. Fentiman,et al.  Autoantibodies to the 90kDa heat shock protein and poor survival in breast cancer patients. , 1998, European Journal of Cancer.

[46]  G. Steele,et al.  Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[47]  P A Ward,et al.  Measurement of Intracellular Fluorescence of Human Monocytes Relative to Oxidative Metabolism , 1988, Journal of leukocyte biology.

[48]  A. Schonthal.  Targeting endoplasmic reticulum stress for cancer therapy. , 2012, Frontiers in bioscience.

[49]  M. Thomas.  Biological characteristics of cancers in the gallbladder and biliary tract and targeted therapy. , 2007, Critical reviews in oncology/hematology.

[50]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.